ABSTRACT
Objective:To evaluate the effect of Xuebijing injection on inflammatory indexes and immune function in patients with acute exacerbation of chronic obstructive pulmonary disease （AECOPD）. Method:PubMed，Cochrane Library，Embase，Wed of Science，CBM，CNKI，VIP and Wanfang Data Online Knowledge service platform were searched by computer，all of which were up to February 2020. After literature screening and quality evaluation by two researchers independently，relevant data were extracted and Meta-analysis was carried out by RevMan 5.3 software. Result:A total of 21 randomized controlled trials（RCT） were included，involving 1 618 patients. The results of Meta-analysis showed，Xuebijing injection adjuvant therapy was significantly better than the control group in total effective rate ［relative risk（RR）=1.20，95% confidence interval（CI）（1.14，1.27），<italic>P</italic><0.000 01］，C-reactive protein（CRP）［standard mean difference（SMD）=-1.58，95% CI（-1.98， -1.19），<italic>P</italic><0.000 01］，total white blood cell （WBC）［mean difference（MD）=-1.44，95% CI（-1.84，-1.04），<italic>P</italic><0.000 01］，procalcitonin（PCT）［SMD=-0.57，95% CI（-0.74，-0.41），<italic>P</italic><0.000 01］，interleukin-6（IL-6）［SMD=-1.51，95% CI（-2.07，-0.96），<italic>P</italic><0.000 01］，percentage of neutrophils（N%）［MD=-5.35，95% CI（-7.13，-3.58），<italic>P</italic><0.000 01］，and tumor necrosis factor-<italic>α</italic>（TNF-<italic>α</italic>）［SMD=-1.52，95% CI（-2.23，-0.81），<italic>P</italic><0.000 1］， and had positive effects in regulating cellular immune disorders. Conclusion:Xuebijing injection combined with routine treatment can improve the immune function of AECOPD patients，reduce the number of inflammatory markers，neutrophils and CD8<sup>+</sup> T cells， thus modulating the small airway microcirculation to promote inflammatory absorption and inhibit the progression of the disease， with high safety.
ABSTRACT
To systemically evaluate the efficacy and safety of Banmao Capsules in the adjuvant treatment for non-small cell lung cancer(NSCLC). All of randomized controlled trials(RCT) about Banmao Capsules in adjuvant treatment for non-small cell lung cancer were retrieved in PubMed, EMbase, Cochrane Library, CNKI, VIP, CBM, WanFang database from database inception to August 2019. Two researchers extracted data and assessed literature quality separately, and made a Meta-analysis by RevMan 5.3 software. Thirteen trials involving 1 148 patients, including 595 in treatment group and 553 in control group, were enrolled in the review. The Meta-analysis showed that compared with conventional treatment, adjuvant treatment of NSCLC with Banmao Capsules can enhance the objective tumor response rate(RR=1.43,95%CI[1.30,1.58],P<0.01), and the disease control rate(RR=1.16,95%CI[1.11,1.22],P<0.01); improve the quality of life(RR=1.56,95%CI[1.27,1.92],P<0.01); reduce the incidence of myelosuppression(RR=0.41,95%CI[0.26,0.66],P<0.01), gastrointestinal reactions(RR=0.46,95%CI[0.33,0.65],P<0.01), liver and kidney dysfunction(RR=0.44,95%CI[0.29,0.66],P<0.01). The results showed that in the treatment of NSCLC, Banmao Capsules can increase the short-term efficacy, improve the quality of life of patients, and reduce the side effects of platinum-based chemotherapy drugs. More high-quality and large-scale randomized controlled trials are required in the future.
Subject(s)
Humans , Capsules , Carcinoma, Non-Small-Cell Lung , Drugs, Chinese Herbal , Lung Neoplasms , Quality of LifeABSTRACT
OBJECTIVE@#To evaluate the effectiveness and safety of Chinese medicine (CM) for Idiopathic pulmonary fibrosis (IPF) patients.@*METHODS@#To screened relevant articles, PubMed, Cochrane Library, Excerpta Medica Datase (EMBASE), China National Knowledge Infrastructure (CNKI), Chinese VIP Information (VIP), Wanfang Database and Chinese Biomedical Database (CBM) were searched in English or Chinese until December 2015 for randomized controlled trials, which compared CM treatment (CM group) with Western medicine or placebo (control group) on IPF. The outcome measures included acute exacerbation, pulmonary function, the St George's respiratory questionnaire (SGRQ) scores, 6-minute walk test (6MWT) distance, adverse events and mortality.@*RESULTS@#This meta-analysis included 25 randomized controlled trials involving 1,471 patients. Compared with the control group, CM group was superiori in reducing the risk of exacerbation [relative risk (RR)=0.40, 95% CI 0.22 to 0.72, P0.05). This meta-analysis also revealed that CM therapy significantly decreased the SGRQ score (SMD=-0.60, 95% CI-1.14 to-0.05, P0.05) between CM and control groups.@*CONCLUSIONS@#The pooled outcomes suggest that CM treatment appears benefit in reducing the risk of exacerbation, improving lung function and decreasing the incidence of adverse effects and enhancing the quality of life. However, the outcomes were limited because of the low quality of the included studies. More rigorous clinic trials need to be carried out to provide sufficient and accurate evidence in the future.